Basiliximab News
Antibody Reduces Rejection in High-risk Kidney Transplants
Nearly 70 percent of kidney transplant patients get short-term drug therapy initially administered during surgery to help prevent rejection. In the first head-to-head comparison of the two drugs most commonly given to ward off...
Induction therapy post-heart transplantation with basiliximab is safer than muromonab
In a recent heart transplantation study, induction therapy with basiliximab was safer and better tolerated than muromonab, without significant differences in efficacy outcomes.
Cerimon licenses Novartis bowel disease drug
Cerimon Pharmaceuticals has licensed the exclusive worldwide rights from Novartis Pharma to develop and commercialize Simulect for the treatment of inflammatory bowel disease.
Cerimon Pharmaceuticals Licenses Exclusive Worldwide Rights to Simulect(R) for the Treatment of Inflammatory Bowel Disease
South San Francisco, Calif. -- Cerimon Pharmaceuticals, Inc. announced today that it has licensed from Novartis Pharma AG the exclusive worldwide rights to develop and commercialize Simulect® (basiliximab) for the treatment of...
Basiliximab Plus Tacrolimus Reduce Liver Transplant Rejection, Increase Survival
Basiliximab in a tacrolimus-based immunosuppressive regimen is effective in reducing incidences of acute cellular rejection (ACR) and improving ACR-free survival after orthotopic liver transplantation (OLTx), without increasing...